Sunnyvale, CA, United States of America

Jan Jozef Scicinski

USPTO Granted Patents = 4 

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2010-2019

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations by Jan Jozef Scicinski in Pharmaceutical Dosage Forms

Introduction

Jan Jozef Scicinski is an accomplished inventor based in Sunnyvale, California, with a strong focus on innovations in oral pharmaceutical dosage forms. He holds four patents, primarily related to controlled release formulations suitable for administering methylphenidate, a medication widely used for attention deficit disorders.

Latest Patents

Scicinski's latest patents include advancements in oral pharmaceutical dosage forms that cater to both standard and abuse-resistant formulations of methylphenidate. His inventive contributions provide significant methods for treating Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD) through these oral dosage forms. The patents emphasize not only controlled release mechanisms but also the safety profiles required to prevent misuse.

Career Highlights

Throughout his career, Jan Jozef Scicinski has worked with notable companies such as Durect Corporation and Nuada, LLC. His experience in these organizations reflects his commitment to advancing pharmaceutical technologies and his expertise in developing innovative solutions for critical health issues.

Collaborations

Scicinski has collaborated with prominent individuals in the field, including William W. Van Osdol and Huey-Ching Su. These collaborations have likely enabled him to enhance his research and development efforts, leading to successful implementations of his patents in the pharmaceutical industry.

Conclusion

Jan Jozef Scicinski's contributions to pharmaceutical innovations, particularly concerning controlled release dosage forms, represent a significant step forward in the treatment of ADD and ADHD. His patents not only demonstrate his creativity and expertise as an inventor but also promise to influence future practices in drug formulation and delivery. With a record of collaboration and a focus on safety, Scicinski continues to be a key player in advancing pharmaceutical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…